BTL Vanquish Cleared for Nonsurgical Abdomen Reduction

BTL Vanquish Cleared for Nonsurgical Abdomen Reduction

The U.S. Food and Drug Administration (FDA) approved the BTL Vanquish (BTL Industries) device for circumferential reduction of the abdomen area. The platform features a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application (without touching patients’ skin). It creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue.

“FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” said Andrea Morrison, BTL director of clinical development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”

For more information, visit

Photo copyright Getty Images.

More in Treatments